Cost-utility analysis of difelikefalin for the treatment of moderate to severe Chronic Kidney Disease associated-Pruritus (CKD-aP) in adult patients receiving haemodialysis in Spain
Difelikefalin could be a cost-effective option compared to BSC for the management of CKD-aP in adult haemodialysis patients within the Spanish NHS setting. Considering the unmet needs, these results support the convenience of incorporating difelikefalin in routine clinical practice in Spain.
Authors
- J. Emilio Sánchez-Álvarez (ORCID: https://orcid.org/0000-0002-4431-3223)
- Isabel De La Paz Cañizares
- Rafáel Sánchez (ORCID: https://orcid.org/0000-0002-5105-4207)
- Olga Ruiz‐Andrés (ORCID: https://orcid.org/0000-0003-2592-9599)
- José Luís Poveda (ORCID: https://orcid.org/0000-0003-1800-6198)
- Antonio Ramírez de Arellano
Institutions
- Hospital Universitario La Paz (ES)
- Hospital Universitari i Politècnic La Fe (ES)
- Health Economics and Outcomes Research (United Kingdom) (GB)
- Hospital Universitario De Cabueñes (ES)
- Vifor Pharma (United States) (US)
Publication Details
- Journal
- Journal of Medical Economics
- Published
- 2025-05-24
- DOI
- https://doi.org/10.1080/13696998.2025.2501874
- Primary Topic
- Dermatology and Skin Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00